AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA - Yahoo Finance

AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA  Yahoo Finance

AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases